.jpg)
.png)
It is a great time to be a clinical lipidologist and I want to thank all of the readers for a wonderful year as co-editor of LipidSpin! It has been the year of the PCSK9 inhibitor introduction and that has captured everyone’s attention. But that is not all that is going on in clinical lipidology; our field is rolling and we have tried to cover as much of it as possible in the LipidSpin this past year.
Article By:
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
The annual Potpourri edition of the LipidSpin is one of my favorites. What is published typically reflects what is in the forefront of the minds of several clinical lipidologists and clinical lipid specialists.
Article By:
Professor, Clinical Pharmacy and Family Medicine
University of Colorado Denver
Anchutz Medical Campus
Aurora, CO
Diplomate, Accreditation Council for Clinical Lipidology
In April 2016, an expert consensus decision pathway on the role of non-statin therapies for lowering LDL-C in the management of atherosclerotic cardiovascular disease (ASCVD) risk was published in the Journal of the American College of Cardiology. This document, which was endorsed by the National Lipid Association (NLA), and with the diligent and consistent work of our Immediate
Article By:
President, National Lipid Association
Consultative Education Specialist
Cardiovascular Risk Intervention
University of Pennsylvania Health System – Retired
Philadelphia, PA
Diplomate, Accreditation Council for Clinical Lipidology
In order to bring further insight and understanding surrounding PCSK9 antibodies and their use in clinical practice, the NLA will host an in-depth supplemental symposium to be held in conjunction with the NLA 2016 Fall Clinical Lipid Update. This 2-hour symposium, held Friday, August 26 from 6:45–9:00 p.m., will present the latest data and usage guidelines surrounding this new class of lipid-lowering therapies.
The new ICD-10 Codes were released by the Center for Medicare & Medicaid Services (CMS). Two new specific codes for FH have been approved:
- E78.01: Familial hypercholesterolemia
- Z83.42: Family history of familial hypercholesterolemia
The National Lipid Association (NLA) in collaboration with the FH Foundation submitted a proposal to the ICD-10 Coordination and Maintenance Committee to create new, specific ICD-10 codes for FH in January 2014.
It is an honor and a privilege to serve as the President of the Southeast Lipid Association (SELA) for the next 12 months. I can only hope to emulate the energy, enthusiasm, and leadership skills of those persons preceding me. But also, I would like to bring a fresh perspective as a full-time practicing lipidologist, hoping to guide our regional chapter in making contributions of knowledge and practical resources to clinicians who see patients on a regular basis.
It is truly an honor to serve as President of the Midwest Lipid Association; following in the steps of those who have brought energy, knowledge, enthusiasm, and creativity to the role.
Although an interventional cardiologist from the beginning of coronary intervention, I have been passionate about clinical lipidology since the mid 1990's and became a Diplomate of the American Board of Clinical Lipidology in 2006. The NLA/PLA has enhanced my practice and changed my focus to prevention and treating patients with lipid disorders. I owe much to the PLA/NLA and will continue to give back to this great organization by service, participation, and contributing to its growth and influence. I encourage everyone to explore this unique and fascinating opportunity.
The 2015 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw yet another significant increase — from 3.904 (2014) to 4.906 (2015). The Journal is now ranked 23rd out of 253 journals in its category (pharmacology and pharmacy). The Thomson-Reuters Impact Factor represents the ratio of articles quoted in other scientific publications
James A. Underberg, MD, Elected by NLA Members during the 2016 NLA Scientific Sessions in New Orleans
The National Lipid Association (NLA) announces the appointment of James A. Underberg, MD, MS, FACPM, FACP, FASPC, FNLA, as president-elect. NLA members voted on the slate of new nominees during the annual business meeting in New Orleans on May 21, 2016.